Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NYSE:ANVS NASDAQ:ELDN NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.90-10.0%$1.11$0.40▼$2.27$101.75M1.21840,255 shs418,539 shsANVSAnnovis Bio$2.27+0.2%$2.42$1.11▼$10.54$44.15M1.63411,104 shs131,224 shsELDNEledon Pharmaceuticals$2.75-3.8%$2.69$2.32▼$5.54$164.37M0.4497,793 shs224,138 shsPEPGPepGen$4.94-0.4%$1.99$0.88▼$9.94$162.69M1.962.07 million shs629,076 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-3.21%+20.57%+72.95%+360.00%+25.60%ANVSAnnovis Bio+1.35%+10.43%-2.01%-11.26%-73.31%ELDNEledon Pharmaceuticals+0.70%+12.60%+5.54%-16.37%+9.16%PEPGPepGen-3.31%+6.90%+254.29%+327.59%-46.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.90-10.0%$1.11$0.40▼$2.27$101.75M1.21840,255 shs418,539 shsANVSAnnovis Bio$2.27+0.2%$2.42$1.11▼$10.54$44.15M1.63411,104 shs131,224 shsELDNEledon Pharmaceuticals$2.75-3.8%$2.69$2.32▼$5.54$164.37M0.4497,793 shs224,138 shsPEPGPepGen$4.94-0.4%$1.99$0.88▼$9.94$162.69M1.962.07 million shs629,076 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-3.21%+20.57%+72.95%+360.00%+25.60%ANVSAnnovis Bio+1.35%+10.43%-2.01%-11.26%-73.31%ELDNEledon Pharmaceuticals+0.70%+12.60%+5.54%-16.37%+9.16%PEPGPepGen-3.31%+6.90%+254.29%+327.59%-46.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.57Moderate Buy$3.3073.68% UpsideANVSAnnovis Bio 2.33Hold$17.33665.27% UpsideELDNEledon Pharmaceuticals 2.40Hold$10.00263.64% UpsidePEPGPepGen 2.33Hold$8.4070.01% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ALXO, ELDN, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/30/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/27/2025ALXOALX OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ELDNEledon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025PEPGPepGenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/25/2025PEPGPepGenStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $12.009/25/2025PEPGPepGenWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $9.009/25/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $12.009/24/2025PEPGPepGenGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.009/9/2025PEPGPepGenGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$6.009/3/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $10.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$2.14 per shareN/AANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.05 per shareN/APEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$134.85M-$2.20N/AN/AN/AN/A-115.67%-84.82%11/6/2025 (Estimated)ANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)PEPGPepGen-$89.98M-$2.96N/AN/AN/AN/A-92.51%-70.39%11/6/2025 (Estimated)Latest ANVS, ALXO, ELDN, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/12/2025Q2 2025ALXOALX Oncology-$0.46-$0.49-$0.03-$0.49N/AN/A8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/7/2025Q2 2025PEPGPepGen-$0.85-$0.70+$0.15-$0.70N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.114.524.52ANVSAnnovis BioN/A7.657.65ELDNEledon PharmaceuticalsN/A8.128.12PEPGPepGenN/A4.744.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%ANVSAnnovis Bio15.83%ELDNEledon Pharmaceuticals56.77%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%ANVSAnnovis Bio20.80%ELDNEledon Pharmaceuticals12.30%PEPGPepGen4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology4053.55 million42.31 millionOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionablePEPGPepGen3032.80 million31.29 millionNot OptionableANVS, ALXO, ELDN, and PEPG HeadlinesRecent News About These CompaniesInsiders Snap Up $54M in Biotech and Offshore Driller Stocks4 hours ago | 247wallst.comWedbush Predicts PepGen's Q3 Earnings (NASDAQ:PEPG)October 4 at 2:19 AM | americanbankingnews.comPepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle SocietyOctober 2, 2025 | finance.yahoo.comPepGen Inc.: PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle SocietyOctober 2, 2025 | finanznachrichten.deWedbush Issues Negative Outlook for PepGen EarningsOctober 2, 2025 | marketbeat.comPepGen (NASDAQ:PEPG) Major Shareholder Science Enterprises Plc Oxford Buys 200,000 SharesOctober 2, 2025 | insidertrades.comScience Enterprises Plc Oxford Purchases 200,000 Shares of PepGen (NASDAQ:PEPG) StockOctober 1, 2025 | marketbeat.comRA Capital discloses increased PepGen stake at 29%October 1, 2025 | msn.comPepGen (PEPG) Price Target Increased by 21.95% to 8.50October 1, 2025 | msn.comPepGen, Inc. $PEPG Shares Sold by Goldman Sachs Group Inc.October 1, 2025 | marketbeat.comPepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM DataSeptember 30, 2025 | insidermonkey.comWhat is Wedbush's Estimate for PepGen FY2028 Earnings?September 29, 2025 | marketbeat.comBrokerages Set PepGen, Inc. (NASDAQ:PEPG) Price Target at $8.40September 28, 2025 | americanbankingnews.comPepGen (NASDAQ:PEPG) Price Target Raised to $9.00 at WedbushSeptember 27, 2025 | americanbankingnews.comPepGen (NASDAQ:PEPG) Stock Price Expected to Rise, HC Wainwright Analyst SaysSeptember 27, 2025 | americanbankingnews.comPepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesSeptember 26, 2025 | finance.yahoo.comPepGen’s stock up 120% on DM1 trial successSeptember 26, 2025 | msn.comPepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional SharesSeptember 26, 2025 | businesswire.comPepGen (PEPG) Skyrockets 121% on Stellar Experimental Treatment Trial ResultsSeptember 26, 2025 | insidermonkey.comPepGen (NASDAQ:PEPG) Price Target Raised to $12.00 at Stifel NicolausSeptember 26, 2025 | americanbankingnews.comWhy Is PepGen Stock (PEPG) Up 125% Today?September 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANVS, ALXO, ELDN, and PEPG Company DescriptionsALX Oncology NASDAQ:ALXO$1.90 -0.21 (-9.95%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Annovis Bio NYSE:ANVS$2.26 +0.01 (+0.22%) As of 12:31 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Eledon Pharmaceuticals NASDAQ:ELDN$2.75 -0.11 (-3.85%) As of 12:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.PepGen NASDAQ:PEPG$4.94 -0.02 (-0.38%) As of 12:33 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal 2 Defense Stocks Riding 2025’s Massive Momentum Wave Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? Best Stocks Under $15? 3 Low-Priced Picks With Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
